As with primaquine, tafenoquine can cause severe hemolytic anemia in people with G6PD deficiency. Those with partial deficiency that may be missed by qualitative testing may also be at risk for hemolysis. Hydroxychloroquine and weight gain Lyme biaxin plaquenil Tafenoquine is an anti-malaria medicine that works by interfering with the growth of parasites in the red blood cells of the human body. Parasites that cause malaria typically enter the body through the bite of a mosquito. Malaria is common in areas such as Africa, South America, and Southern Asia. Tafenoquine is an 8-aminoquiniline related to primaquine with pre-clinical activity against a range of malaria species. We treated two acute cases of vivax malaria with tafenoquine 800 mg over three days alone, instead of conventional chloroquine 1500 mg over three days and primaquine 420 mg over 14 days. Tafenoquine is used in combination with another medication such as chloroquine to treat and prevent the return of malaria. Malaria is caused by infection with a parasite spread by mosquito bite. Tafenoquine use in people with G6PD deficiency or unknown G6PD status is contraindicated. Therefore, physicians must perform G6PD testing before prescribing tafenoquine. Act with chloroquine tafenoquine Guidance for Using Tafenoquine for Prevention and Antirelapse., Treatment of acute vivax malaria with tafenoquine. Plaquenil 400 mg side effectsHow to bill for following plaquenil retinaEffect of plaquenil on free light chains Tafenoquine is an investigational medicine that has completed phase III studies. If approved, it would be the first new medicine for relapsing malaria in over 60 years. Tafenoquine will potentially offer a single-dose cure for the liver-stage of P. vivax infections and will be administered alongside a standard 3-day chloroquine or potentially an ACT treatment regimen. Tafenoquine - a potential medicine to prevent P. vivax.. Tafenoquine 150 mg tablet Kaiser Permanente. Guidance for Using Tafenoquine for Prevention and.. Single-dose tafenoquine 300 mg coadministered with chloroquine for P vivax malaria relapse prevention was more efficacious than chloroquine alone, with a similar safety profile. As a result, it has been selected for further clinical assessment in phase 3. The 8-aminoquinoline tafenoquine TFQ, a primaquine derivative, is currently in late-stage clinical development for the radical cure of P. vivax. Here drug interactions between TFQ and chloroquine and six artemisinin-combination therapy ACT partner drugs in P. falciparum asexual stages and gametocytes were investigated. TFQ was mostly synergistic with the ACT-partner drugs in asexual parasites regardless of genetic backgrounds. The limited evidence available supports both the use of chloroquine and an ACT for P. ovale and P. malariae. ACT seems to be preferable for optimal treatment of P. knowlesi. ACT is at least equivalent to chloroquine in effectively treating non-falciparum malaria.